Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

MAP Pharmaceuticals Phase 3 Trial Of Levadex™ Migraine Product Candidate Meets All Four Primary Endpoints
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX™ orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing.
generic viagra online
New Online Curriculum Educates Physicians About Kidney Disease In Older Patients
The fastest-growing group of patients initiating dialysis is patients 75 years old and older; providing the best care for this group of patients presents significant challenges. The American Society of Nephrology (ASN) introduces the first-ever online curriculum to address aging and the kidney. The curriculum, based on the Accreditation Council for Graduate Medical Education (ACGME)"s six core competences of patient care, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, professionalism, and systems-based practice, answers questions about the management of elderly patients.
News of the day
Massachusetts Health Insurance Law Has Increased Access To Care, Though Residents' Ability To Obtain Treatment Hampered By Provider Supply, Study Find
Since the implementation of the Massachusetts health insurance law in 2006, more residents have health coverage and increased access to care, but rising health care costs combined with the current economic recession could undermine some of the law"s successes, according to the third annual "Update on Health Reform in Massachusetts" report by the Urban Institute, the Boston Globe reports. The study was funded by the Blue Cross and Blue Shield of Massachusetts Foundation, the Robert Wood Johnson Foundation and the Commonwealth Fund, and published in the journal Health Affairs.For the report, Sharon Long of the Urban Institute and colleagues surveyed about 4,000 Massachusetts adults in 2007 and 2008 and compared their health care habits with those of residents surveyed in 2006 -- just after the law went into effect. Researchers found that although there were initial gains in health care affordability, there are now some signs that an increasing number of state residents are reporting problems paying for medical bills, and an increasing number of people -- especially lower-income residents -- not seeking care because of costs (Lazar, Boston Globe, 5/28). One in five adults reported being told in the past 12 months that a physician or clinic was not accepting new patients or would not see patients with their type of insurance (Sack, New York Times, 5/28). Lower-income residents had more difficulties finding a physician than higher-income residents, with 24% of residents enrolled in state-subsidized health plans, saying they were told that a physician did not accept their insurance, compared with 7% of residents with private coverage (Boston Globe, 5/28). Additional Findings
Oncology

D-Pharm Receives FDA Clearance To Commence A Phase III Trial Of DP-b99 In Acute Stroke Patients

D-Pharm announced today that its Investigational New Drug (IND) application for a pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients has been approved by the US Food and Drug Administration (FDA). D-Pharm plans to initiate the trial in the coming months, in over 100 clinical sites in North America, Europe, South Africa and Israel. The forthcoming Phase III trial is a randomized, double blind, placebo-controlled study (study acronym MACSI: Membrane Activated Chelator Stroke Intervention). It is designed to compare the effect on ischemic stroke outcome between a placebo group and a group of patients treated with 1 mg/kg/day of DP-b99 for 4 consecutive days. D-Pharm plans to enroll 770 moderate to severely affected ischemic stroke patients worldwide, with first patients expected to be recruited in Israel and South Africa. Dr. Gilad Rosenberg, D-Pharm"s VP Clinical Development commented, "The FDA"s IND procedure involved review of the entire DP-b99 data set. Following 30 days for review of our IND application, the FDA has no further questions relating to DP-b99"s CMC, preclinical and clinical data package. I"m very pleased that the Agency is satisfied with our data and we can move forward with this important study without delay." Prior to the IND submission D-Pharm successfully completed the program outlined at the pre-IND meeting held with the FDA in January 2008. The program included additional toxicity studies, a drug interaction study with rtPA, and an interaction study with warfarin in healthy volunteers, as well as scale-up and optimization of the DP-b99 manufacturing process. About DP-b99 DP-b99 is a unique neuroprotective drug that addresses an array of brain damaging processes occurring in stroke patients and emerged from D-Pharm"s proprietary Membrane Activated Chelator (MAC) platform technology. D-Pharm successfully completed extensive testing of DP-b99 in pre-clinical and then in Phase I and Phase II clinical studies. Both preclinical and clinical studies indicate a favorable efficacy and safety profile for DP-b99. In the recently completed Phase IIb trial in 150 ischemic stroke patients, DP-b99 increased by two-fold the percentage of patients that completely recovered from ischemic stroke. DP-b99 may be administered within a nine hour therapeutic window. About Stroke Every year approximately 780,000 Americans have a new or recurrent stroke. The second most common cause of death worldwide, stroke is also the leading cause of serious long-term disability; 15% to 30% of stroke survivors experience permanent disability. According to the American Heart Association, the estimated direct and indirect cost in 2009 of stroke in the US is $68.9 billion. Only about 2 to 5% of acute stroke patients are eligible for treatment with tissue plasminogen activator (tPA), the only FDA approved drug treatment for acute stroke. $68.9 billion. Only about 2 to 5% of acute stroke patients are eligible for treatment with tissue plasminogen activator (tPA), the only FDA approved drug treatment for acute stroke. About D-Pharm Ltd. D-Pharm is a clinical stage, biopharmaceutical company pioneering the development of lipid-like therapeutics and has generated a rich pipeline of patent protected proprietary products. D-Pharm"s pipeline includes advanced clinical stage products DP-b99 for treatment of acute ischemic stroke patients and DP-VPA, a novel drug for treatment of epilepsy, bipolar disorder and prophylaxis of migraine. DP-460 is in preclinical development intended as an oral, disease-modifying therapy for Alzheimer"s disease. Other mimics of bioactive lipids, LipidoMimetix, are at an earlier developmental stage, for cancer. D-Pharm Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009